| Date | Title | | | 02/01/10 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor
Conference on February 8, 2010| SAN DIEGO, Feb 01, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIO CEO & Investor
Conference 2010 on Monday, February 8, 2010, at 3:00 p.m. Eastern Time
at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACA... |
|  | | 11/09/09 | ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 9, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the third quarter
ended September 30, 2009.
ACADIA reported a net loss of $8.7 million, or $0.23 per common share,
for the third quarte... |
| | | 11/02/09 | ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009|
ACADIA to Host Conference Call and Webcast on Monday, November 9,
2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the third quar... |
| | | 10/20/09 | ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009| SAN DIEGO--(BUSINESS WIRE)--Oct. 20, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIOCOM Investor Conference
2009 on Monday, October 26, 2009 at 2:30 p.m. Pacific Time at the Hyatt
Regency in San Diego.
A live webcast of AC... |
| | | 10/06/09 | ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2009| SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the JMP Securities Healthcare
Focus Conference on Tuesday, October 6, 2009 at 3:00 p.m. Eastern Time
at The New York Palace Hotel in New York City.
... |
| | | 10/06/09 | ACADIA Pharmaceuticals Provides Update on Pimavanserin Collaborative Development Program| SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today provided an update on its Phase III program with pimavanserin for
Parkinson’s disease psychosis (PDP), which is being pursued in
collaboration with Biovail Laboratories International SRL (&... |
| | | 09/01/09 | ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis|
Pimavanserin Misses Primary Endpoint of Antipsychotic Efficacy; Meets
Key Secondary Endpoint of Motoric Tolerability
Conference Call Scheduled for Today, September 1, at 8:00 A.M.
Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Sep. 1, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line
results from the first pivotal Phase III trial with pimavanserin in
patients with Parkinson’s disease psychosis, or P... |
| | | 08/05/09 | ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the second quarter
and six months ended June 30, 2009.
ACADIA reported a net loss of $12.7 million, or $0.34 per common share,
for the ... |
| | | 07/29/09 | ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009| ACADIA to Host Conference Call and Webcast on Wednesday, August 5, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the second quarter ended June 30, 20... |
| | | 06/03/09 | ACADIA Pharmaceuticals to Present at the Eighth Annual Needham Life Sciences Conference on June 10, 2009| SAN DIEGO--(BUSINESS WIRE)--Jun. 3, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Eighth Annual Needham Life
Sciences Conference on Wednesday, June 10, 2009 at 9:30 a.m. Eastern
Time at The New York Palace Hotel in New York City.
... |
| | | 05/13/09 | ACADIA Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference on May 19, 2009| SAN DIEGO--(BUSINESS WIRE)--May. 13, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Eighth Annual JMP Securities
Research Conference on Tuesday, May 19, 2009 at 2:30 p.m. Pacific Time
at The Ritz-Carlton Hotel in San Francisco.
... |
| | | 05/11/09 | ACADIA Pharmaceuticals Reports First Quarter 2009 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May. 11, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the first quarter
ended March 31, 2009.
ACADIA reported a net loss of $15.0 million, or $0.40 per common share,
for the first quarter ... |
| | | 05/06/09 | ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis| Top-Line Data Expected in the Third Quarter of 2009
SAN DIEGO & TORONTO--(BUSINESS WIRE)--May. 6, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Biovail Corporation
(NYSE:BVF) (TSX:BVF), today announced the completion of enrollment in
the first pivotal Phase III clinical trial of pimavanserin in patients
with Parkinson’s disease psychosis (PDP). Top-line results from this
trial are expected to be announced by the end of the third quarter of
20... |
| | | 05/05/09 | ACADIA Pharmaceuticals to Announce First Quarter 2009 Financial Results on May 11, 2009| ACADIA to Host Conference Call and Webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 5, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the first quarter ended March 31, 2009 on... |
| | | 05/04/09 | ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America| Conference Call Scheduled for Today, May 4, 2009, at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May. 4, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced that it has
established a collaboration with Biovail Laboratories International SRL,
a subsidiary of Biovail Corporation, to co-develop and commercialize
pimavanserin, ACADIA’s proprietary and selective 5-HT2A inverse
agonist, in the United States and Canada. ACADIA retains rights t... |
| | | 03/25/09 | ACADIA Pharmaceuticals and Meiji Seika Kaisha Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs| Meiji Seika Granted Rights to Develop and Commercialize Products in Asian Territory; ACADIA Retains All Rights in the Rest of the World
SAN DIEGO--(BUSINESS WIRE)--Mar. 25, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Meiji Seika Kaisha, Ltd.
(TSE:2202) today announced that they have established a collaboration to
develop and commercialize a novel class of pro-cognitive drugs to treat
patients with schizophrenia and related disorders in Japan and several
... |
| | | 03/09/09 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2008| SAN DIEGO--(BUSINESS WIRE)--Mar. 9, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the fourth quarter
and year ended December 31, 2008.
ACADIA reported a net loss of $14.0 million, or $0.38 per common share,
for the fo... |
| | | 03/04/09 | ACADIA Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference on March 11, 2009| SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the Barclays Capital Global
Healthcare Conference on Wednesday, March 11, 2009, at 9:30 a.m. Eastern
Time at the Loews Miami Beach Hotel in Miami Beach, Florida.... |
| | | 03/02/09 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009| ACADIA to Host Conference Call and Webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Mar. 2, 2009--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its unaudited financial results for
the fourth quarter and year ended Decemb... |
| | | 02/03/09 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at the BIO CEO & Investor
Conference 2009 on Tuesday, February 10, 2009, at 10:00 a.m. Eastern
Time at The Waldorf=Astoria Hotel in New York City.
A live webcast o... |
| | | 01/07/09 | ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel ER-beta Agonists for the Treatment of Parkinson’s Disease| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it has been awarded a grant from The Michael J. Fox
Foundation for the development of novel estrogen receptor beta (ER-beta)
agonists for the treatment of Parkinson’s disease. The grant of up to
... |
| | | 11/25/08 | ACADIA Pharmaceuticals to Present at The 20th Annual Piper Jaffray Health Care Conference on December 3, 2008| SAN DIEGO, Nov 25, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at The 20th Annual Piper
Jaffray Health Care Conference on Wednesday, December 3, 2008, at 10:30
a.m. Eastern Time at The New York Palace Hotel in New York City.
A live ... |
| | | 11/05/08 | ACADIA Pharmaceuticals Reports Third Quarter 2008 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the third quarter ended September 30,
2008.
ACADIA reported a net loss of $15.6 million, or $0.42 per common
share, for the third quarter of 2008 compared to a net loss of $16.0
mil... |
| | | 11/03/08 | ACADIA Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008| SAN DIEGO--(BUSINESS WIRE)--Nov. 3, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at The Rodman & Renshaw 10th Annual Healthcare
Conference on Tuesday, November 11, 2008, at 11:35 a.m. Eastern Time
at The New York Palace Hotel in New York City.
A live webcast of ACADIA's presen... |
| | | 10/29/08 | ACADIA Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 5, 2008| ACADIA to Host Conference Call and Webcast on Wednesday, November
5, 2008, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the third quarter
ended September 30, 2008... |
| | | 10/21/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the following
investor conferences:
-- The BIOCOM Investor Conference 2008 on Tuesday, October 28,
2008, at 3:30 p.m. Pacific Time at the Hyatt Regency in San
Diego.
-- BIO I... |
| | | 09/29/08 | ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008| SAN DIEGO--(BUSINESS WIRE)--
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the JMP Securities
Healthcare Focus Conference on Monday, October 6, 2008, at 1:00 p.m.
Eastern Time at Le Parker Meridien Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible o... |
| | | 09/05/08 | ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility| SAN DIEGO--(BUSINESS WIRE)--Sept. 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it filed a registration statement as required under the terms of its
previously announced Committed Equity Financing Facility (CEFF) with
Kingsbridge Capital Limited.
Under the terms of the CEFF, ACADIA has acces... |
| | | 08/28/08 | ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008| SAN DIEGO, Aug 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will present at The Thomas Weisel Partners 2008
Healthcare Conference on Thursday, September 4, 2008, at 2:40 p.m.
Eastern Time at the Four Seasons Boston Hotel.
A live webcast of AC... |
| | | 08/05/08 | ACADIA Pharmaceuticals Secures Committed Equity Financing Facility| SAN DIEGO, Aug 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it has entered into a Committed Equity
Financing Facility (CEFF) with Kingsbridge Capital Limited in which
Kingsbridge has committed to provide up to $60 million of capital
during the next three years through the purchase... |
| | | 08/05/08 | ACADIA Pharmaceuticals Announces Second Quarter 2008 Financial Results and Strategic Restructuring| SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the second quarter ended June 30, 2008
and announced a strategic restructuring.
ACADIA will focus on developing a portfolio of its four most
advanced product candidates, consisting o... |
| | | 07/29/08 | ACADIA Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008| ACADIA to Host Conference Call and Webcast on Tuesday, August 5,
2008, at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--July 29, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the second quarter
ended June 30, 2008 on... |
| | | 06/16/08 | ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial| -- Conference Call Scheduled for Today, June 16, 2008, at 8:30
a.m. Eastern Time --
SAN DIEGO--(BUSINESS WIRE)--June 16, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD) today announced results from its Phase IIb trial
with ACP-104 for the treatment of schizophrenia. The study did not
meet its primary endpoint of antipsychotic efficacy or any of the
secondary endpoints. Neither dose of ACP-104 demonstrated improved
efficacy as compared to placebo. The most c... |
| | | 06/04/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--June 4, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The Seventh Annual Needham & Company Biotechnology and Medical
Technology Conference on Wednesday, June 11, 2008, at 1:30
p.m. Eastern Time at ... |
| | | 05/14/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--May 14, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The 2008 Citi Investment Research Global Health Care
Conference on Thursday, May 22, 2008, at 10:30 a.m. Eastern
Time at the Hilton New York i... |
| | | 05/05/08 | ACADIA Pharmaceuticals Reports First Quarter 2008 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system (CNS) disorders, today reported
its unaudited financial results for the first quarter ended March 31,
2008.
ACADIA reported a net loss of $16.4 million, or $0.44 per common
share, for the first quarter of 2008 compared to a net loss of $12.6
mil... |
| | | 05/05/08 | ACADIA Pharmaceuticals Announces Election of Laura A. Brege to Board of Directors| SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced the
election of Laura A. Brege to its board of directors. Ms. Brege will
fill a vacancy on the Board and serve as a Class III director. The
terms of the Class III directors expire at the annual meeting of
stockholders in 2... |
| | | 04/30/08 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--April 30, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
Deutsche Bank's 33rd Annual Health Care Conference on
Wednesday, May 7, 2008, at 9:30 a.m. Eastern Time at the
InterContinental Boston Hote... |
| | | 04/28/08 | ACADIA Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 5, 2008| ACADIA to Host Conference Call and Webcast on Monday, May 5, 2008,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--April 28, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the first quarter
ended March 31, 2008 on M... |
| | | 04/16/08 | ACADIA Pharmaceuticals to Present Data from Its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting| SAN DIEGO--(BUSINESS WIRE)--April 16, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
the company will present data from its previously reported Phase II
trial with pimavanserin for Parkinson's disease psychosis (PDP) at the
60th American Academy of Neurology Annual Meeting on April 16, 2008 in
Chica... |
| | | 04/04/08 | ACADIA Pharmaceuticals to Present Preclinical Data on ACP-104, ACP-105 and Its Muscarinic Discovery Program at Experimental Biology 2008 Meeting| SAN DIEGO--(BUSINESS WIRE)--April 4, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
the company will present preclinical data on its ACP-104 schizophrenia
program, its ACP-105 Selective Androgen Receptor Modulator (SARM)
program, and its muscarinic discovery program at the Experimental
Biology 2008... |
| | | 03/31/08 | ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis| SAN DIEGO--(BUSINESS WIRE)--March 31, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it has initiated its second Phase III trial designed to evaluate the
safety and efficacy of pimavanserin as a treatment for Parkinson's
disease psychosis (PDP).
"The start of our second Phase III pivotal trial r... |
| | | 03/28/08 | ACADIA Pharmaceuticals to Present at the 8th Annual Fortis Bank Biotechnology Conference| SAN DIEGO, Mar 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at The 8th Annual
Fortis Bank Biotechnology Conference on Thursday, April 3, 2008, at
10:00 a.m. Western European Time at the Four Seasons Hotel London in
London, England.
About ACADIA Pharmaceuticals
... |
| | | 03/11/08 | ACADIA Pharmaceuticals to Present at Lehman Brothers 11th Annual Global Healthcare Conference| SAN DIEGO--(BUSINESS WIRE)--March 11, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at Lehman Brothers 11th Annual Global Healthcare
Conference on Tuesday, March 18, 2008, at 2:00 p.m. Eastern Time at
the Loews Miami Beach Hotel in Miami Beach, Florida.
A live webcast of ACADIA... |
| | | 03/05/08 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007|
SAN DIEGO--(BUSINESS WIRE)--March 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD),
a biopharmaceutical company utilizing innovative technology to fuel drug discovery
and clinical development of novel treatments for central nervous system disorders,
today reported its unaudited financial results for the fourth quarter and year
ended December 31, 2007.
ACADIA reported a net loss of $17.0 million, or $0.46 per common share, for
the fourth quarter of 2007 compared to a n... |
| | | 02/27/08 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 5, 2008| ACADIA to Host Conference Call and Webcast on Wednesday, March 5,
2008, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2008--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the fourth quarter
and year ended December ... |
| | | 02/12/08 | ACADIA Pharmaceuticals Appoints John J. Kaiser as Vice President, Strategic Marketing and Commercial Development| SAN DIEGO, Feb 12, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced the appointment of John J. Kaiser as Vice
President, Strategic Marketing and Commercial Development. Mr. Kaiser
joins ACADIA from Eli Lilly & Co. where he held a variety of marketing
and commercial management positions over a... |
| | | 02/05/08 | ACADIA Pharmaceuticals Announces Presentation of Data on Pimavanserin Co-Therapy at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders| New Data Demonstrate Less Increase in Serum Glucose Levels With Pimavanserin Co-Therapy
SAN DIEGO, Feb 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that Murray Rosenthal, D.O., a Fellow of
the American Psychiatric Association, will present data from ACADIA's
pimavanserin Phase II schiz... |
| | | 02/04/08 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2008| SAN DIEGO, Feb 04, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the BIO CEO &
Investor Conference 2008 on Tuesday, February 12, 2008, at 10:15 a.m.
Eastern Time at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible... |
| | | 12/26/07 | ACADIA Pharmaceuticals to Present at the 26th Annual JP Morgan Healthcare Conference on January 7, 2008| SAN DIEGO, Dec 26, 2007 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it will present at the 26th Annual JP
Morgan Healthcare Conference on Monday, January 7, 2008, at 2:00 p.m.
Pacific Time at The Westin St. Francis Hotel in San Francisco.
A live webcast of ACADIA's presentation will be ac... |
| | | 12/14/07 | ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule| Top-Line Results Expected in Q2 2008
SAN DIEGO--(BUSINESS WIRE)--Dec. 14, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it has completed enrollment in its Phase IIb clinical trial with
ACP-104 in patients with schizophrenia significantly ahead of
expectations. ACADIA expects to report top-line... |
| | | 12/06/07 | ACADIA Pharmaceuticals to Webcast Its Analyst and Investor Meeting on December 14, 2007| SAN DIEGO--(BUSINESS WIRE)--Dec. 6, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will host a live webcast of its Analyst and Investor Meeting to be
held in New York City on Friday, December 14, 2007, from 8:00 a.m. to
10:30 a.m. Eastern Time.
The program will feature presentations by ACAD... |
| | | 11/07/07 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The JMP Securities Healthcare Focus Conference on Tuesday,
November 13, 2007, at 10:00 a.m. Eastern Time at The Four
Seasons Hotel in Boston.
... |
| | | 11/05/07 | ACADIA Pharmaceuticals Reports Third Quarter 2007 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the third quarter and nine months
ended September 30, 2007.
ACADIA reported a net loss of $16.0 million, or $0.43 per common
share, for the third quarter of 2007 compared to a net los... |
| | | 11/02/07 | ACADIA Pharmaceuticals to Present Preclinical Data on Its Advanced Schizophrenia Programs at the 37th Annual Meeting of the Society for Neuroscience| Data Demonstrate Cognitive Advantages of Co-Therapy with
Pimavanserin and Stand-alone Therapy with ACP-104
SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
the company will present preclinical data on its two advanced
schizophrenia programs at the 37th A... |
| | | 10/29/07 | ACADIA Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 5, 2007| ACADIA to Host Conference Call and Webcast on Monday, November 5,
2007, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the third quarter
ended September 30, 2007... |
| | | 10/26/07 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--Oct. 26, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The BIOCOM Investor Conference on Thursday, November 1, 2007,
at 3:00 p.m. Pacific Time at the San Diego Marriott Del Mar in
San Diego.
Th... |
| | | 10/03/07 | ACADIA Pharmaceuticals to Present at BIO InvestorForum 2007 on October 10, 2007| SAN DIEGO--(BUSINESS WIRE)--Oct. 3, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at BIO InvestorForum 2007 on Wednesday, October 10,
2007, at 12:15 p.m. Pacific Time at The Palace Hotel in San Francisco.
A live webcast of ACADIA's presentation will be accessible on the
company'... |
| | | 09/25/07 | ACADIA Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index| SAN DIEGO--(BUSINESS WIRE)--Sept. 25, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it has been selected to be one of the inaugural companies in the new
NASDAQ(R) NeuroInsights(R) Neurotech Index. The index launched today
and is calculated on a price return basis (NASDAQ:NERV) and a total
return ba... |
| | | 09/19/07 | ACADIA Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference| SAN DIEGO--(BUSINESS WIRE)--Sept. 19, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the 2007 UBS Global Life Sciences Conference on
Wednesday, September 26, 2007, at 2:00 p.m. Eastern Time at the Grand
Hyatt New York Hotel in New York City.
A live webcast of ACADIA's presenta... |
| | | 08/06/07 | ACADIA Pharmaceuticals Reports Second Quarter 2007 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Aug. 6, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the second quarter and six months
ended June 30, 2007.
ACADIA reported a net loss of $10.8 million, or $0.29 per common
share, for the second quarter of 2007 compared to a net loss of... |
| | | 08/01/07 | ACADIA Pharmaceuticals to Present at the Canaccord Adams 27th Annual Global Growth Conference| SAN DIEGO--(BUSINESS WIRE)--Aug. 1, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at The Canaccord Adams 27th Annual Global Growth
Conference on Wednesday, August 8, 2007, at 10:30 a.m. Eastern Time at
the InterContinental Hotel in Boston.
A live webcast of ACADIA's presentation... |
| | | 07/30/07 | ACADIA Pharmaceuticals to Announce Second Quarter 2007 Financial Results on August 6, 2007| ACADIA to Host Conference Call and Webcast on Monday, August
6, 2007, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--July 30, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the second quarter
ended June 30, 2007 on Monday, August 6, 200... |
| | | 07/16/07 | ACADIA Pharmaceuticals Earns Milestone on Advancement of Glaucoma Drug Candidate| SAN DIEGO--(BUSINESS WIRE)--July 16, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
Allergan, Inc. will initiate an exploratory clinical study with a
small molecule drug candidate for the treatment of glaucoma, which
triggered a milestone payment to ACADIA. The selective muscarinic
compound emanates... |
| | | 06/26/07 | ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia| SAN DIEGO--(BUSINESS WIRE)--June 26, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced the
initiation of a Phase IIb clinical trial designed to evaluate the
safety and efficacy of ACP-104 as a treatment for patients with
schizophrenia.
"ACP-104 represents a promising new approach to the treatment of
s... |
| | | 06/11/07 | ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis| SAN DIEGO, Jun 11, 2007 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced the initiation of its first Phase III trial
designed to evaluate the safety and efficacy of pimavanserin as a
treatment for Parkinson's disease psychosis (PDP).
"The start of the first Phase III pivotal trial in our
pimavanse... |
| | | 05/24/07 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--May 24, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
-- The Bank of America 2007 Health Care Conference on Thursday,
May 31, 2007, at 9:20 a.m. Pacific Time at the Four Seasons
Hotel in Las Ve... |
| | | 05/08/07 | ACADIA Pharmaceuticals Reports First Quarter 2007 Financial Results| SAN DIEGO, May 08, 2007 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today reported its unaudited financial results for the
first quarter ended March 31, 2007.
ACADIA reported a net loss of $12.6 million, or $0.42 per common
share, for the first quarter of 2007 compared to a net loss of $9.5
million, or $0.3... |
| | | 05/01/07 | ACADIA Pharmaceuticals to Announce First Quarter 2007 Financial Results on May 8, 2007| ACADIA to Host Conference Call and Webcast on Tuesday, May 8,
2007, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May 1, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the first quarter
ended March 31, 2007 on Tuesday... |
| | | 04/24/07 | Pimavanserin Approved by USAN as Nonproprietary Name for ACADIA Drug Candidate ACP-103| SAN DIEGO--(BUSINESS WIRE)--April 24, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
the United States Adopted Names (USAN) Council has approved the
nonproprietary name "pimavanserin tartrate" for ACADIA's drug
candidate ACP-103.
The USAN Council serves health professionals in the United States
... |
| | | 04/20/07 | ACADIA Pharmaceuticals Announces Exercise of Over-Allotment by Underwriters| SAN DIEGO--(BUSINESS WIRE)--April 20, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD) announced today that the underwriters have
exercised in full their over-allotment option to purchase 862,500
shares of the Company's common stock, in connection with its public
offering that priced on April 4, 2007. Including the over-allotment
shares being purchased, the offering totaled 6,612,500 shares at a
public offering price of $15.50 per share, resulting in aggregate net
proceeds to ACADIA of... |
| | | 04/18/07 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--April 18, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The 7th Annual Fortis Bank Biotechnology Conference on
Wednesday, April 25, 2007 at 10:30 a.m. Western European Time
at the Four Seasons Hote... |
| | | 04/04/07 | ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering| SAN DIEGO--(BUSINESS WIRE)--April 4, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD) announced today the pricing of its public offering
of 5,750,000 shares of its common stock. The public offering price of
$15.50 per share will result in gross proceeds of $89.1 million and
net proceeds, after underwriting commissions and other offering
expenses, of $83.5 million to ACADIA. ACADIA also granted the
underwriters a 30-day option to purchase up to 862,500 additional
shares of its common s... |
| | | 04/02/07 | ACADIA Pharmaceuticals Announces Proposed Public Stock Offering| SAN DIEGO--(BUSINESS WIRE)--April 2, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD) announced today the filing of a preliminary
prospectus supplement to its effective shelf registration statement
previously filed with the Securities and Exchange Commission relating
to a proposed underwritten public offering of 5,000,000 shares of its
common stock. In connection with the offering, ACADIA also plans to
grant the underwriters an option to purchase up to 750,000 additional
shares of its ... |
| | | 03/29/07 | ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research| SAN DIEGO--(BUSINESS WIRE)--March 29, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
the company will present at the 2007 International Congress on
Schizophrenia Research, held from March 28 through April 1, 2007, in
Colorado Springs, Colorado. Presentations will cover ACADIA's two
schizophrenia pr... |
| | | 03/19/07 | ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial| -- Enhanced Antipsychotic Efficacy --
-- Faster Onset of Action --
-- Less Weight Gain --
-- Conference Call Scheduled for Today, March 19, 2007, at 9:00 a.m. Eastern Time –
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive
top-line results from its Phase II schizophrenia co-therapy trial with
ACP-103, ACADIA's proprietary and selective 5-HT2A inverse agonist.
The trial evaluated ACP-103 co-therapy when used together... |
| | | 03/14/07 | ACADIA Pharmaceuticals to Present at Lehman Brothers 10th Annual Global Healthcare Conference| SAN DIEGO--(BUSINESS WIRE)--March 14, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at Lehman Brothers 10th Annual Global Healthcare
Conference on Tuesday, March 20, 2007, at 10:45 a.m. Eastern Time at
the Loews Miami Beach Hotel in Miami Beach, Florida.
A live webcast of ACADIA... |
| | | 03/06/07 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2006| SAN DIEGO--(BUSINESS WIRE)--March 6, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the fourth quarter and year ended
December 31, 2006.
ACADIA reported a net loss of $12.5 million, or $0.42 per common
share, for the fourth quarter of 2006 compared to a net loss of... |
| | | 02/27/07 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2006 Financial Results on March 6, 2007| ACADIA to Host Conference Call and Webcast on Tuesday, March 6,
2007, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the fourth quarter
and year ended December 3... |
| | | 02/06/07 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 13, 2007| SAN DIEGO--(BUSINESS WIRE)--Feb. 6, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the BIO CEO & Investor Conference 2007 on Tuesday,
February 13, 2007, at 11:15 a.m. Eastern Time at The Waldorf=Astoria
Hotel in New York City.
A live webcast of ACADIA's presentation will be ac... |
| | | 01/03/07 | ACADIA Pharmaceuticals to Present at the 25th Annual JP Morgan Healthcare Conference on January 11, 2007| SAN DIEGO--(BUSINESS WIRE)--Jan. 3, 2007--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the 25th Annual JP Morgan Healthcare Conference on
Thursday, January 11, 2007, at 1:00 p.m. Pacific Time at The Westin
St. Francis Hotel in San Francisco.
A live webcast of ACADIA's presentation... |
| | | 12/04/06 | ACADIA Pharmaceuticals Adds Complementary Intellectual Property for Serotonin Platform| SAN DIEGO, Dec 04, 2006 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and
clinical development of novel treatments for central nervous system
disorders, today announced that it has expanded and further
strengthened the intellectual property portfolio for its serotonin
platform by entering into an agreement to license certain intellectual
property rights from Ipsen (Euronext:IPN), an innovatio... |
| | | 11/06/06 | ACADIA Pharmaceuticals Reports Third Quarter 2006 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 6, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the third quarter and nine months
ended September 30, 2006.
ACADIA reported a net loss of $11.3 million for the third quarter
of 2006 compared to a net loss of $12.3 million for the t... |
| | | 11/01/06 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--Nov. 1, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The Rodman & Renshaw 8th Annual Healthcare Conference on
Wednesday, November 8, 2006 at 11:20 a.m. Eastern Time at The
New York Palace Hot... |
| | | 10/30/06 | ACADIA Pharmaceuticals to Announce Third Quarter 2006 Financial Results on November 6, 2006|
SAN DIEGO--(BUSINESS WIRE)--Oct. 30, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the third quarter
ended September 30, 2006 on Monday, November 6, 2006, after the U.S.
financial markets close. ACADIA's management will host a conference
call and... |
| | | 10/23/06 | ACADIA Pharmaceuticals to Support Launch of New Company Focused on Substance Abuse Therapeutics| Mark R. Brann, Ph.D., to Become CEO of Abbey PharmaceuticalsSAN DIEGO, Oct 23, 2006 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it
will provide initial seed funding to help establish Abbey
Pharmaceuticals, a startup biotechnology company focused on
medications for substance abuse. The new company will be led by Mark
R. Brann, Ph.D., who has resigned from his position as President and
Chief Scientific Officer and as a member of the Board of Directors of... |
| | | 10/11/06 | ACADIA Pharmaceuticals to Present at BIO InvestorForum 2006 on October 18, 2006| SAN DIEGO--(BUSINESS WIRE)--Oct. 11, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at BIO InvestorForum 2006 on Wednesday, October 18,
2006, at 11:00 a.m. Pacific Time at The Palace Hotel in San Francisco.
A live webcast of ACADIA's presentation will be accessible on the
company... |
| | | 09/25/06 | ACADIA Pharmaceuticals Announces Accelerated Timing of ACP-103 Phase II Trial in Patients with Schizophrenia; Top-Line Results for Complete 400-Patient Study Expected in Q1 2007| SAN DIEGO--(BUSINESS WIRE)--Sept. 25, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today provided an
update on the timing of its Phase II adjunctive therapy trial with
ACP-103 in patients with schizophrenia. ACADIA reported that
enrollment in the clinical trial is significantly ahead of schedule,
which should enable t... |
| | | 09/12/06 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--Sept. 12, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
The Bank of America 36th Annual Investment Conference on
Tuesday, September 19, 2006, at 10:00 a.m. Pacific Time at The
Ritz-Carlton Hotel i... |
| | | 08/08/06 | ACADIA Pharmaceuticals Reports Second Quarter 2006 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today reported its
unaudited financial results for the second quarter and six months
ended June 30, 2006.
ACADIA reported a net loss of $11.9 million for the second quarter
of 2006 compared to a net loss of $6.0 million for the second... |
| | | 08/03/06 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--Aug. 3, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the following investor conferences:
-- The Canaccord Adams 26th Annual Summer Seminar on Thursday,
August 10, 2006, at 1:00 p.m. Eastern Time at the Boston
Marriott Long Wharf... |
| | | 08/02/06 | ACADIA Pharmaceuticals to Announce Second Quarter 2006 Financial Results on August 8, 2006; ACADIA to Host Conference Call and Webcast on Tuesday, August 8, 2006, at 5:00 p.m. Eastern Time| SAN DIEGO--(BUSINESS WIRE)--Aug. 2, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report its unaudited financial results for the second quarter
ended June 30, 2006 on Tuesday, August 8, 2006, after the U.S.
financial markets close.
Uli Hacksell, Ph.D., Chief Executive Officer, and Thoma... |
| | | 07/13/06 | ACADIA Pharmaceuticals Announces Encouraging Results from Initial Clinical Trials with ACP-104 in Patients with Schizophrenia| SAN DIEGO--(BUSINESS WIRE)--July 13, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced
results from three initial clinical studies of ACP-104 in patients
with schizophrenia. The results of these studies demonstrated that
ACP-104 is safe and well tolerated after repeated dosing of up to 600
mg per day, and t... |
| | | 06/20/06 | ACADIA Pharmaceuticals to Present at the Jefferies Life Sciences Conference on June 27, 2006| SAN DIEGO--(BUSINESS WIRE)--June 20, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at the Jefferies Life Sciences Conference on Tuesday,
June 27, 2006, at 10:45 a.m. Eastern Time at the Mandarin Oriental
Hotel in New York City.
A live webcast of ACADIA's presentation will be acc... |
| | | 06/08/06 | ACADIA Pharmaceuticals to Present at Needham's Fifth Annual Biotechnology and Medical Technology Conference| SAN DIEGO--(BUSINESS WIRE)--June 8, 2006--ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will present at Needham & Company's Fifth Annual Biotechnology and
Medical Technology Conference on Thursday, June 15, 2006, at 10:00
a.m. Eastern Time at The New York Palace Hotel in New York City.
A live web... |
| | | 06/05/06 | ACADIA Pharmaceuticals Announces Appointment of Roger G. Mills, M.D., as Executive Vice President, Development| SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced the appointment of Roger G. Mills,
M.D., as Executive Vice President, Development, effective June 30, 2006. Dr.
Mills will be responsible for leading ACADIA's global drug development
activities and will report to Uli Ha... |
| | | 05/15/06 | ACADIA Pharmaceuticals Added to NASDAQ Biotech Index| SAN DIEGO, May 15, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it was selected for addition to
the NASDAQ Biotechnology Index (NBI), effective as of the market's opening on
May 22, 2006.
"We are pleased to be included in the NASDAQ Biotechnology Inde... |
| | | 05/10/06 | ACADIA Pharmaceuticals Reports First Quarter 2006 Financial Results| SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported its unaudited financial results for
the first quarter ended March 31, 2006.
ACADIA reported a net loss of $9.5 million for the first quarter of 2006
compared to a net loss of $5.6 million for the first quarter of 2005... |
| | | 05/08/06 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will present at the
following investor conferences:
The Rodman & Renshaw 3rd Annual Global Healthcare Conference on Monday,
May 15, 2006, at 10:50 a.m. Central European Time at Le Meridien Beach
... |
| | | 05/03/06 | ACADIA Pharmaceuticals to Announce First Quarter 2006 Financial Results on May 10, 2006| ACADIA to Host Conference Call and Webcast on Wednesday, May 10, 2006, at
5:00 p.m. Eastern Time
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will report its unaudited
financial results for the first quarter ended March 31, 2006... |
| | | 04/27/06 | ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering| SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today the pricing of its public offering of 4,947,229
shares of its common stock. The public offering price of $12.00 per share
resulted in gross proceeds of $59.4 million and net proceeds, after
underwriting commissions and other offering expenses, of $55.6 million to
ACADIA. ACADIA also granted the underwriters a 30-day option to purchase up
to 742,084 additional shares of its common ... |
| | | 04/24/06 | ACADIA Pharmaceuticals Announces Proposed Public Stock Offering| SAN DIEGO, April 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today the filing of a preliminary prospectus
supplement to its effective shelf registration statement previously filed with
the Securities and Exchange Commission relating to a proposed underwritten
public offering of $75 million of its common stock. In connection with the
offering, ACADIA also plans to grant the underwriters an option to purchase
approximately ... |
| | | 04/19/06 | ACADIA Pharmaceuticals Announces Positive Clinical Trial Results Demonstrating That ACP-103 Increases Slow Wave Sleep| SAN DIEGO, April 19 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) today reported top-line results from a proof-of-concept
clinical study that assessed the effect of ACP-103 on deep, or slow wave,
sleep in healthy older volunteers using polysomnography (PSG). Results of the
study demonstrated that ACP-103 induced a robust and statistically significant
increase in slow wave sleep that was dose-related. ACP-103 treatment also had
a positive impact on measures for ... |
| | | 03/23/06 | ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease| Conference Call Scheduled for Today, March 23, 2006 at 5:00 p.m. Eastern Time
SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) today reported results from its Phase II clinical trial of
ACP-103 in patients with Parkinson's disease suffering from treatment-induced
psychosis. ACP-103 met the primary endpoint of the clinical trial, which was
motoric tolerability as measured by the Unified Parkinson's Disease Rating
Scale (UPDRS), by demonstrating t... |
| | | 03/02/06 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO, March 2, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will present at the
following investor conferences:
The 5th Annual JMP Securities Research Conference on Wednesday,
March 8, 2006, at 8:40 a.m. Pacific Time at The Ritz-Carlton ... |
| | | 03/01/06 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2005| SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported its unaudited financial results for
the fourth quarter and year ended December 31, 2005.
ACADIA reported a net loss of $10.2 million for the fourth quarter of 2005
compared to a net loss of $7.3 million for the fourt... |
| | | 02/22/06 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2005 Results on March 1, 2006| ACADIA to Host Conference Call and Webcast on Wednesday, March 1, 2006, at
5:00 p.m. Eastern Time
SAN DIEGO, Feb. 22 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will report its unaudited
financial results for the fourth quarter and year ended D... |
| | | 02/21/06 | ACADIA Pharmaceuticals Announces Advancements in Two Preclinical Programs| SAN DIEGO, Feb 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it has nominated a
non-steroidal and selective androgen receptor agonist, ACP-105, as a
development candidate. ACADIA also announced that it has advanced its program
based on the discovery... |
| | | 02/07/06 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference 2006 on February 14, 2006| SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that Uli Hacksell, Ph.D., Chief
Executive Officer, will present at the BIO CEO & Investor Conference 2006 on
Tuesday, February 14, 2006, at 12:00 p.m. Eastern Time at the Waldorf=Astoria
Hotel in New York City.
A li... |
| | | 01/17/06 | ACADIA Pharmaceuticals Announces Additional $10 Million Equity Investment by Sepracor| SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system (CNS) disorders, today announced that Sepracor Inc.
(Nasdaq: SEPR) has completed the second $10 million purchase of ACADIA common
stock in connection with the collaboration between the two companies formed in
January 2005. Sepracor's purchase wa... |
| | | 01/09/06 | ACADIA Pharmaceuticals Announces Appointment of David C. Furlano, Ph.D., as Vice President, Regulatory Affairs| SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system (CNS) disorders, today announced the appointment of
David C. Furlano, Ph.D., as Vice President, Regulatory Affairs.
"Dr. David Furlano brings to ACADIA more than 15 years of regulatory
affairs experience. His broad experience of leading regul... |
| | | 12/15/05 | ACADIA Pharmaceuticals Discovers Novel Isoform-Selective Retinoic Acid Receptor Agonists| SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced publication of research, in both the
Journal of Medicinal Chemistry and in Biochemical Pharmacology, that reports
ACADIA's discovery of novel isoform-selective retinoic acid receptor (RAR)
agonists and a highly effectiv... |
| | | 12/01/05 | ACADIA Pharmaceuticals Reports Results From Phase II Study of ACP-103 in Schizophrenia Patients With Haloperidol-Induced Akathisia| SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported results from a Phase II study that
showed that ACP-103 reduced haloperidol-induced akathisia, a debilitating
extrapyramidal side effect, in patients with schizophrenia.
This study is one of two Phase II clinical trial... |
| | | 11/10/05 | Acadia Pharmaceuticals Reports Third Quarter 2005 Financial Results| SAN DIEGO, Nov 10, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported its unaudited financial results for
the third quarter and nine months ended September 30, 2005.
ACADIA reported a net loss of $12.3 million for the third quarter of 2005,
compared to a net loss... |
| | | 11/10/05 | ACADIA Pharmaceuticals Announces Initial Results From Ongoing Single-Dose Clinical Trial of ACP-104 in Schizophrenia Patients| SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced initial results from an ongoing
clinical trial of ACP-104 in patients with schizophrenia. ACP-104 is
currently being evaluated in three clinical trials, all of which are being
conducted in patients with schizophrenia a... |
| | | 11/03/05 | ACADIA Pharmaceuticals to Announce Third Quarter 2005 Financial Results on November 10, 2005| ACADIA to Host Conference Call and Webcast on Thursday, November 10, 2005, at
5:00 p.m. Eastern Time
SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will report its unaudited
financial results for the third quarter ended September 3... |
| | | 11/01/05 | ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 8, 2005| SAN DIEGO, Nov 01, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare
Conference on Tuesday, November 8, 2005, at 8:00 a.m. Eastern Time at The New
York Palace Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors... |
| | | 10/13/05 | ACADIA Pharmaceuticals to Present at BIO InvestorForum 2005 on October 20, 2005| SAN DIEGO, Oct 13, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at BIO InvestorForum 2005 on Thursday, October 20, 2005,
at 12:00 p.m. Pacific Time at The Palace Hotel in San Francisco.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors section and an
archived recording will be avai... |
| | | 10/03/05 | ACADIA Pharmaceuticals Earns Milestone on Advancement of Neuropathic Pain Clinical Program| SAN DIEGO, Oct 03, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it has received a milestone
payment from Allergan, Inc. (NYSE: AGN) resulting from the advancement of the
companies' clinical program directed at novel treatments for neuropathic pain.
Un... |
| | | 09/22/05 | ACADIA Pharmaceuticals Study Identifies Molecular Properties of ACP-104 That Predict Unique Antipsychotic Activity| ACP-104, Major Metabolite of Clozapine, Partially Activates Dopamine D2 and
D3 Receptors
SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced publication of research in the
Journal of Pharmacology and Experimental Therapeutics (JPET) tha... |
| | | 09/20/05 | ACADIA Pharmaceuticals to Present at the 2005 UBS Global Life Sciences Conference on September 27, 2005| SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the 2005 UBS Global Life Sciences Conference on
Tuesday, September 27, 2005, at 10:00 a.m. Eastern Time at the Grand Hyatt
New York in New York City.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors section and an
archived recording wi... |
| | | 09/16/05 | ACADIA Pharmaceuticals Officially Opens New Chemistry R&D Facility in Sweden| SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today officially opened its modern chemistry
research and development facility in Malmo, Sweden. The new facility
consolidates ACADIA's presence in Scandinavia and provides increased access to
a highly skilled and well-educated workforce... |
| | | 09/13/05 | ACADIA Pharmaceuticals Announces Election of Michael T. Borer to Board of Directors| SAN DIEGO, Sept 13, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced the election of Michael T. Borer to
its board of directors. The board of directors also appointed Mr. Borer to
its audit committee. Mr. Borer will serve as a Class I director. The terms
of t... |
| | | 08/24/05 | ACADIA Pharmaceuticals Comments on Civil Litigation| Company and Officers to Vigorously Contest Verdict
SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that a verdict has been rendered in
a civil action brought by a former employee of ACADIA.
The civil action against ACADIA and two of its executive officers, Ro... |
| | | 08/17/05 | ACADIA Pharmaceuticals to Present at the 8th Annual San Diego Growth Conference on August 19, 2005| SAN DIEGO, Aug. 17 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the 8th Annual San Diego Growth Conference on Friday,
August 19, 2005, at 10:00 a.m. Pacific Time at the Hilton La Jolla Torrey
Pines in La Jolla, California.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors section and an
archived record... |
| | | 08/10/05 | ACADIA Pharmaceuticals Reports Second Quarter 2005 Financial Results| SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported its unaudited financial results for
the second quarter and six months ended June 30, 2005.
ACADIA reported a net loss of $6.0 million for the second quarter of 2005,
compared to a net loss of $5.9 million for the secon... |
| | | 08/03/05 | ACADIA Pharmaceuticals to Announce Second Quarter 2005 Financial Results on August 10, 2005| ACADIA to Host Conference Call and Webcast on Wednesday, August 10, 2005
at 4:30 p.m. Eastern Time
SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will report its unaudited
financial results for the second quarter ended June 30, 200... |
| | | 07/27/05 | ACADIA Pharmaceuticals to Present at the 25th Annual Adams Harkness Summer Seminar on August 3, 2005| SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the 25th Annual Adams Harkness Summer Seminar on
Wednesday, August 3, 2005, at 11:00 a.m. Eastern Time at the Marriott Long
Wharf Hotel in Boston.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors section and an
archived recording will be ... |
| | | 06/22/05 | ACADIA Pharmaceuticals Announces Encouraging Interim Results From Ongoing Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease| SAN DIEGO, June 22 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system (CNS) disorders, today reported encouraging results from a
planned interim trend analysis of its ongoing multi-center Phase II clinical
trial of ACP-103 for treatment-induced psychosis in patients with Parkinson's
disease.
The ongoing double-b... |
| | | 05/19/05 | ACADIA Pharmaceuticals to Present at the Fourth Annual Needham Biotechnology Conference| SAN DIEGO, May 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the Fourth Annual Needham Biotechnology Conference on
Thursday, May 26, 2005, at 3:30 p.m. Eastern Time at the New York Palace Hotel
in New York City.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors section and an
archived ... |
| | | 05/17/05 | ACADIA Pharmaceuticals Expands Technology Platform to Target Tyrosine Kinase Linked Receptors| Novel Assay Technologies Highlighted at Molecular Pharmacology Gordon Conference and ASCO Annual Meeting 2005 SAN DIEGO, May 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system (CNS) disorders, today reported on the development of assay
technologies for a major class of drug targets, tyrosine kinase l... |
| | | 05/11/05 | ACADIA Pharmaceuticals Reports First Quarter 2005 Financial Results| SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported its unaudited financial results for
the first quarter ended March 31, 2005.
ACADIA reported a net loss of $5.6 million for the first quarter of 2005,
compared to a net loss of $6.5 million for the first quarter of 2004.... |
| | | 05/10/05 | ACADIA Pharmaceuticals to Present at Banc of America Securities Health Care Conference 2005| SAN DIEGO, May 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the Banc of America Securities Health Care Conference
2005 on Tuesday, May 17, at 12:00 p.m. Pacific Time at the Four Seasons Hotel
in Las Vegas.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors section and an
archived recor... |
| | | 05/04/05 | ACADIA Pharmaceuticals to Announce First Quarter 2005 Financial Results on May 11, 2005| ACADIA to Host Conference Call and Webcast on Wednesday, May 11, 2005 at 4:30 p.m. Eastern Time SAN DIEGO, May 4, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will report its unaudited
financial results for the first quarter ended March 31, 2005 on Wednesday,
May... |
| | | 04/28/05 | ACADIA Pharmaceuticals Announces Election of Mary Ann Gray, Ph.D. to Board of Directors| SAN DIEGO, April 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced the election of Mary Ann Gray, Ph.D.
to its board of directors on April 27, 2005. The board of directors also
appointed Dr. Gray to its audit committee. Dr. Gray will serve as a Class I
director and has ... |
| | | 04/15/05 | ACADIA Pharmaceuticals Announces $36 Million Financing| SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it has entered into a
definitive purchase agreement for a $36 million private placement of newly
issued shares of common stock and the concurrent issuance of warrants for the
purchase of additional shares of common st... |
| | | 03/31/05 | ACADIA Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference on April 7, 2005| SAN DIEGO, March 31, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the Future Leaders in the Biotech Industry Conference
on Thursday, April 7, 2005, at 9:30 a.m. Eastern Time at the Millennium
Broadway Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors section and an
... |
| | | 03/07/05 | ACADIA Announces Management Appointments in Business Development and Research and Development| SAN DIEGO, March 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced the appointments of Brian Lundstrom
to Senior Vice President, Business Development, Daniel P. van Kammen, M.D.,
Ph.D., to Vice President, Clinical Development, and Douglas W. Bonhaus, Ph.D.,
to Vice Preside... |
| | | 03/03/05 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2004| SAN DIEGO, March 3, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported its unaudited financial results for
the fourth quarter and year ended December 31, 2004.
ACADIA reported a net loss of $7.3 million for the fourth quarter of 2004,
compared to a net loss of $4.3 million ... |
| | | 02/24/05 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2004 Financial Results on March 3, 2005| ACADIA to Host Conference Call and Webcast on Thursday, March 3, 2005 at 4:30 p.m. Eastern Time SAN DIEGO, Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will report its financial
results for the fourth quarter and year ended December 31, 2004 on Thursday,
... |
| | | 02/22/05 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO, Feb 22, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the following upcoming investor conferences:
* The Wells Fargo Securities HealthCare Conference on Tuesday, March 1,
2005, at 10:00 a.m. Eastern Time at the St. Regis Hotel in New York
City.
* The SunTrust Robinson Humphrey Therapeutics Conference on Tuesday,
March 1... |
| | | 02/17/05 | ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 24, 2005| SAN DIEGO, Feb 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the BIO CEO & Investor Conference on Thursday,
February 24, 2005, at 2:30 pm Eastern Time at the Waldorf=Astoria Hotel in New
York City.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors section and an
archived recording will... |
| | | 01/19/05 | ACADIA Pharmaceuticals to Present at the Piper Jaffray 17th Annual Health Care Conference on January 26, 2005| SAN DIEGO, Jan. 19 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the Piper Jaffray 17th Annual Health Care Conference
on January 26, 2005, at 3:30 pm Eastern Time at The Pierre Hotel in New York
City.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investors section and an
archived recording will be available o... |
| | | 01/11/05 | ACADIA Pharmaceuticals Announces Partnership With Sepracor| SAN DIEGO, Jan 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced the formation of a partnership with
Sepracor Inc. (Nasdaq: SEPR) for development of new drug candidates targeted
toward treatment of central nervous system (CNS) disorders.
This research and development ... |
| | | 11/10/04 | ACADIA Pharmaceuticals Reports Third Quarter 2004 Financial Results| SAN DIEGO, Nov 10, 2004 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported financial results for the third
quarter and nine months ended September 30, 2004.
ACADIA reported a net loss of $6.2 million for the third quarter ended
September 30, 2004, compared to a net loss of $3.4 ... |
| | | 11/04/04 | ACADIA Pharmaceuticals Inc. Third Quarter 2004 Earnings Conference Call| SAN DIEGO--(BUSINESS WIRE)--Nov. 4, 2004--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report third quarter 2004 financial results on Wednesday,
November 10, 2004, after the U.S. financial markets close.
ACADIA will host a conference call and webcast on Wednesday,
November 10, 2004 at 4:30 p.m... |
| | | 11/03/04 | ACADIA Pharmaceuticals to Announce Third Quarter 2004 Financial Results on November 10, 2004| Will Host Conference Call and Webcast on Wednesday, November 10, 2004 at
4:30 p.m. EST
SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will report third quarter
2004 financial results on Wednesday, November 10, 2004, after the U.... |
| | | 10/26/04 | ACADIA Pharmaceuticals Earns Milestone on Advancement of Neuropathic Pain Drug| SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that Allergan, Inc. (NYSE: AGN) has
filed an Investigational New Drug application with the FDA covering a small
molecule drug candidate for the treatment of neuropathic pain, triggering a
milestone payment to ACADIA.
... |
| | | 10/19/04 | ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on October 26, 2004| SAN DIEGO, Oct 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive
Officer, will present at the Rodman & Renshaw Techvest 6th Annual Healthcare
Conference on October 26, 2004, at 3:50 pm Eastern Time at the Waldorf=Astoria
Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the investor relations section
and... |
| | | 10/07/04 | ACADIA Pharmaceuticals to Present at the Bio Emerging Company Investor Forum| SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that it will present at the Bio Emerging
Company Investor Forum on Wednesday, October 13, at 2:20 pm PDT. ACADIA's
presentation will be given by Uli Hacksell, Ph.D., its Chief Executive
Officer, and will be webcast from the Sheraton Palace Hotel in San Francisco.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadia-pharm.com, under the inv... |
| | | 09/15/04 | ACADIA Clinical Study Shows ACP-103 Improves Clinical Profile of Antipsychotic Drug Treatment| SAN DIEGO, Sep 15, 2004 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative science to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported results from a clinical study that
assessed the ability of ACP-103, ACADIA's proprietary 5-HT2A inverse agonist,
to reduce the side effects associated with antipsychotic drug treatment with
haloperidol. Results... |
| | | 09/02/04 | ACADIA Pharmaceuticals to Expand Scandinavian Chemistry Operations| SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) and Medeon Science Park today announced plans to establish a
modern chemistry research and development facility in Malmo, Sweden. The new
laboratory, under construction by Medeon Fastigheter AB, is centrally located
within the Medicon Valley region, home to greater than 60 per cent of
Scandinavian pharmaceutical and biotechnology companies.
ACADIA's biological research and clinical development ac... |
| | | 08/11/04 | ACADIA Pharmaceuticals Reports Second Quarter 2004 Financial Results| SAN DIEGO, Aug 11, 2004 /PRNewswire via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative science to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today reported financial results for the second
quarter and six months ended June 30, 2004.
ACADIA reported a net loss of $5.9 million for the second quarter ended
June 30, 2004, compared to a net loss of $3.0 million for the second... |
| | | 08/05/04 | ACADIA Pharmaceuticals to Announce Second Quarter 2004 Financial Results on August 11, 2004| Will Host Conference Call and Webcast on
Wednesday, August 11, 2004 at 4:30 p.m. EDT
SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative science to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced that it will report second quarter
2004 financial results on Wednesday, August 11, 2004, after the U.S. financial
mark... |
| | | 08/05/04 | ACADIA Pharmaceuticals Inc. Second Quarter 2004 Earnings Conference Call| SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2004--ACADIA Pharmaceuticals
Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative
science to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders, today announced that
it will report second quarter 2004 financial results on Wednesday,
August 11, 2004, after the U.S. financial markets close.
ACADIA will host a conference call and webcast on Wednesday,
August 11, 2004 at 4:30 p.m. EDT ... |
| | | 08/03/04 | ACADIA Study Links ACP-104 (N-desmethylclozapine) to Improved Cognition in Schizophrenia Patients| ACADIA's Clinical Development of ACP-104 Supported by The Stanley Medical
Research Institute
SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative science to
fuel drug discovery and clinical development of novel treatments for central
nervous system disorders, today announced publication of research linking the
mechanism of ACP-104 (N-desmethylclozapine) to the ability of ... |
| | | 07/30/04 | ACADIA Pharmaceuticals to Present at the 24th Annual Adams Harkness Summer Seminar on August 5, 2004| SAN DIEGO, Jul 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) announced today that it will present at the 24th Annual Adams
Harkness Summer Seminar on Thursday, August 5, 2004, at 4:00 pm EDT. ACADIA's
presentation will be given by Uli Hacksell, Ph.D., ACADIA's Chief Executive
Officer, and will be webcast from the Marriott Long Wharf Hotel in Boston.
A live webcast of ACADIA's presentation will be accessible on the
company's website, www.acadi... |
| | | 06/29/04 | ACADIA Pharmaceuticals Presents Favorable Results From Phase Ib/IIa Clinical Trial and PET Study of ACP-103| PHILADELPHIA, June 29 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD) presented, at the CNS Diseases Congress held in
Philadelphia, results of a Phase Ib/IIa clinical trial of ACP-103 in patients
with Parkinson's disease and results from a human brain receptor occupancy
study of ACP-103 performed using position emission tomography (PET). Results
of these studies demonstrated that ACP-103, ACADIA's proprietary 5-HT2A
inverse agonist, was safe and well tolerated in Park... |
| | | 05/26/04 | ACADIA Pharmaceuticals Announces Initial Public Offering| SAN DIEGO, May 26 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc.
(Nasdaq: ACAD) today announced the pricing of its initial public offering of
5,000,000 shares of common stock at a price of $7.00 per share. All of the
shares are being offered by ACADIA. ACADIA also granted to the underwriters a
thirty-day option to purchase up to an additional 750,000 shares of common
stock to cover over-allotments. The shares have been listed on The Nasdaq
National Market under the symbol "ACAD."... |
| | | 01/08/04 | ACADIA Pharmaceuticals Achieves Milestone as Allergan Advances Glaucoma Drug Candidate | Selective Muscarinic Compounds Demonstrate Promising Preclinical Profile
SAN DIEGO, CA and COPENHAGEN, DENMARK, January 8, 2004 - ACADIA Pharmaceuticals
announced today that it has achieved a milestone in its collaboration agreement
with Allergan (NYSE: AGN) to discover, develop, and commercialize selective
muscarinic drugs for the treatment of glaucoma. The milestone was triggered
by Allergan's selection of a collaboration compound for further development
and c... |
| | | 08/06/03 | ACADIA Pharmaceuticals Successfully Completes Phase I Clinical Testing of ACP-103 | Proprietary Small Molecule 5-HT2A Inverse Agonist Appears Safe and Well
Tolerated
SAN DIEGO, CA, and COPENHAGEN, DK, August 6, 2003 – ACADIA Pharmaceuticals
announced today that it has successfully completed Phase I clinical testing
of ACP-103, the Company's proprietary small molecule 5-HT2A inverse agonist.
The study was designed to evaluate the safety, tolerability and pharmacokinetics
of ACP-103 following oral administration in normal healthy volunteers. Results ... |
| | | 06/12/03 | ACADIA Pharmaceuticals Expands Private Placement to $28 Million | Gordon Binder of Coastview Capital Appointed to ACADIA's Board of Directors
SAN DIEGO, CA, and COPENHAGEN, DK, June 12, 2003 – ACADIA Pharmaceuticals
announced today that it has completed a follow-on closing of its private placement
to include a new equity investment by funds managed by Coastview Capital, a
life sciences venture capital firm based in Southern California. This new investment
brings the total proceeds of ACADIA's recent private placement to $28 millio... |
| | | 04/15/03 | Allergan and ACADIA Pharmaceuticals Announce New Drug Discovery and Development Collaboration | Collaboration to Pursue Numerous Target-Specific Chemistries in Eye Care
and Other Indications
SAN DIEGO, CA, April 15, 2003 - ACADIA Pharmaceuticals announced today
it has established a new drug discovery and development collaboration with Allergan,
Inc. (NYSE: AGN). The collaboration, which will focus predominantly on eye care
applications, combines ACADIA's chemical-genomics platform and discovery assets
with Allergan's world-class expertise in the discovery, dev... |
| | | 03/28/03 | ACADIA Pharmaceuticals Completes $25 Million Private Placement| Alan G. Walton of Oxford Bioscience Partners Appointed to ACADIA's Board
of Directors
SAN DIEGO, CA, and COPENHAGEN, DK, March 28, 2003 - ACADIA Pharmaceuticals
announced today that it has completed a $25 million private placement of its
preferred stock. The financing round was led by Oxford Bioscience Partners of
Westport Connecticut, and included investments from OrbiMed Advisors LLC, Federated
Kaufmann Fund, LD Pensions, Hambrecht & Quist Capital Management LLC, ... |
| | | 01/22/03 | ACADIA Initiates Clinical Trials for ACP-103 - Initially Targets Treatment-Induced Dysfunction in Parkinson's Disease| SAN DIEGO, CA and COPENHAGEN, DK, January 22, 2003 - ACADIA Pharmaceuticals
announced today that it has initiated Phase I clinical trials for ACP-103, a
small molecule drug candidate that represents an important new approach to amelioration
of treatment-induced dysfunction in Parkinson's disease as well as a range of
neuropsychiatric disorders. ACP-103 originates entirely from ACADIA's internal
discovery and development efforts and represents the first of two proprietary
... |
| | | 12/10/02 | ACADIA Expands Pain Portfolio to Include New GPCR Targets| Discovery of First Small Molecule Agonists for NPFF and MrG Receptors
SAN DIEGO, CA, December 10, 2002 - ACADIA Pharmaceuticals announced
today the discovery of the first small molecule chemistries that activate two
important G-protein coupled receptor (GPCR) targets, the NPFF and the MrG receptors.
Small molecule drugs acting on these recently discovered targets represent a
potential breakthrough in the treatment of pain. ACADIA's novel lead chemistries
broaden the... |
| | | 11/13/02 | Paul S. Anderson, Ph.D., Appointed To ACADIA Pharmaceutical's Scientific Advisory Board| SAN DIEGO, CA and COPENHAGEN, DK, November 13, 2002 - ACADIA Pharmaceuticals
announced today the appointment of Paul S. Anderson, Ph.D., to its Scientific
Advisory Board. Dr. Anderson is one of the world's most highly respected medical
chemists and has nearly 40 years of experience in drug research. Most recently,
Dr. Anderson held the position of Vice President, Drug Discovery at Bristol-Myers
Squibb. Earlier in his career, he held the positions of Vice President of Chemist... |
| | | 09/26/02 | ACADIA Discovers Novel Small Molecule Leads for the V2 Vasopressin Receptor| Chemical-Genomics Platform Enables Discovery Of Small Molecule Activators
Of Numerous Peptide GPCRs
SAN DIEGO, CA and COPENHAGEN, DK, September 26, 2002 - ACADIA Pharmaceuticals
announced today the discovery of small molecule lead chemistries for the V2
Vasopressin receptor. The V2 Vasopressin receptor is the major control mechanism
for the production of urine. Activation of this receptor by ACADIA's lead compounds
resulted in a sustained decrease in urine productio... |
| | | 06/13/02 | ACADIA Applies Chemical Genomics to Discover Small Molecule Leads for Numerous GPCRs and Nuclear Rececptors| Proprietary platform has identified novel chemistries for over 60 targets including the first agonists for HNF4 a and PAR2
SAN DIEGO, CA, June 13, 2002 – ACADIA Pharmaceuticals announced the
successful application of its proprietary chemical-genomics approach to more
than 100 G-protein coupled receptor (“GPCR”) and nuclear receptor targets. The
presentation was made by Mark R. Brann, Ph.D., ACADIA's President and
Chief Scientific Officer, at the Ch... |
| | | 01/03/02 | ACADIA Announces Chemical-Genomics Collaboration with Amgen to Discover Small Molecule Drugs| SAN DIEGO, CA, January 3, 2002 - ACADIA Pharmaceuticals announced today that it has established a collaboration with Amgen (Nasdaq: AMGN) to discover novel small molecule drugs using ACADIA's proprietary chemical-genomics platform. The companies will apply ACADIA's discovery platform to identify small molecule leads for up to twelve genomic targets, including both orphan and known drug targets. These chemical leads will then be used to explore the therapeutic potential of the targets and as s... |
| |
|
